智通财经APP讯,美诺华(603538.SH)公告,公司子公司安徽美诺华药物化学有限公司(简称“安徽美诺华”)收到国家药品监督管理局核准签发的盐酸鲁拉西酮原料药《化学原料药上市申请批准通知书》,该药品适应症为:用于治疗精神分裂症。
智通财经APP讯,美诺华(603538.SH)公告,公司子公司安徽美诺华药物化学有限公司(简称“安徽美诺华”)收到国家药品监督管理局核准签发的盐酸鲁拉西酮原料药《化学原料药上市申请批准通知书》,该药品适应症为:用于治疗精神分裂症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.